Genome Life Sciences lab gets recognition in India

Updated on 12 July 2012

With this recognition, Chennai-based Genome Life Sciences joins a select group of companies in the Indian bioinformatics system biology space

recognition-dsir-genome-life-sciences

The company has received recognition from the DSIR for its in-house R&D facility

New Delhi: Chennai-based bioinformatics and biomarker company Genome Life Sciences (GLS) recently received recognition for its in-house R&D facility from the Department Of Scientific and Industrial Research (DSIR) under the Ministry of Science and Technology, Goevrnment of India.

"We are pleased to receive DSIR recognition for our In-house R&D Unit," said Dr Narinder Singh , Head-Technology Innovation and Commercializing Research of Genome Life Sciences. "This recognition speaks of Genome Life Science's excellent track record of world-class research and technology development in the areas of next generation biomarker research using our patented technology, Functional Genomic fingerprinting, and in bioinformatics product development. This is a very significant milestone in our existence and officially approves that our infrastructure, man-power and scientific work is of world class standard and ready for national and international collaborations and commercializing the technologies in this business space," Dr Singh added.

"Bioinformatics and biomarker research is still in infancy stage in India. This recognition is a boost to Genome Life Science to promote further research in biomarker and bioinformatics and collaborate with other national and international institutions of excellence," he said.
Genome Life Science's R&D facility is to address the speedier development of next generation biomarkers using company's cutting edge functional genomic finger printing technology(FGF) from various sources and evolve clinically meaningful research outputs, diagnostic product development and plant molecular marker for rapid crop breeding programs.

The company is in advance stages of license agreement and knowledge-sharing tie-up with various MNCs in Pharma and agri-biotechnology companies, which will give them access to GLS's expertise and technology in biomarker research programs.

The R&D facility of the company has computer engineers, scientists and managers drawn from some of the world's best institutions across the world and has more than 6 patents world wide and 20 publication in international journals.

Previous 1

Leave a Reply

Post Comment

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X